A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis Clinical Trial

Official title:
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).

Clinical Trial Description

Not provided ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06068465
Study type	Interventional
Source	Tasly Pharmaceutical Group Co., Ltd
Contact	Rui Liu
Phone	022-86343626
Email	liurui2@tasly.com
Status	Recruiting
Phase	Phase 3
Start date	September 27, 2023
Completion date	January 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04373317` - Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis	Phase 4
Completed	`NCT01518309` - An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients	Phase 2
Completed	`NCT00658567` - A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Phase 3
Completed	`NCT00477672` - A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Phase 3
Completed	`NCT01174004` - A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis	Phase 3
Completed	`NCT00550238` - A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Phase 3
Recruiting	`NCT05590637` - Comparing Antipsychotic Medications in LBD Over Time	Phase 4
Approved for marketing	`NCT02762591` - Expanded Access of Pimavanserin for Patients With PD Psychosis	N/A